TOMI Environmental Solutions Expands SteraMist iHP into India's Pharmaceutical Market Through Partner STS Technocrat (India) Pvt. Ltd.
A pharmaceutical customer commitment accompanies joint work on an integrated SteraMist enclosure for the Indian market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TOMI Environmental Solutions (NASDAQ: TOMZ) announced expansion in India's pharmaceutical sector after partner STS Technocrat signed a SteraMist customer.
The new customer is an unnamed pharmaceutical company. STS Technocrat distributes SteraMist and is working with TOMI to manufacture a fully integrated SteraMist iHP enclosure for decontamination. The partner is also pursuing several additional pharmaceutical opportunities. TOMI expects customer referrals to support adoption in India, following the pattern it has seen across U.S. life sciences.
Positive
- Minor pointSTS Technocrat signed a pharmaceutical customer for SteraMist in India.
- Minor pointIntegrated SteraMist iHP enclosure is being developed by STS Technocrat with TOMI for manufacture.
- Minor pointSeveral additional pharmaceutical opportunities are being pursued by STS Technocrat in India.
- Minor point. Forward-looking: it has not happened yet and may not happen.Customer referrals are expected by TOMI to support Indian adoption, following its U.S. life-sciences experience.
Negative
- None.
Details
Market Reaction – TOMZ
On Oct 1, the day this news came out, the latest delayed price for TOMZ is 2.76% above the previous close. The latest delayed price is $1.30. Relative volume is elevated at 2.5x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- India pharmaceutical market
- USD 75.89 billion
- 2026
- Projected India pharmaceutical market
- USD 174.67 billion
- By 2034
- CAGR
- 10.98%
- India pharmaceutical market, 2026–2034
Historical Context
-
Earlier YTD SteraMist iHP enclosure purchase orders documented commercial uptake of the same enclosure line.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
gmp regulatory
cagr financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
STS Technocrat (India) Pvt. Ltd. signs a leading pharmaceutical customer and is building an integrated SteraMist iHP enclosure with TOMI to support growth across India
FREDERICK, Md. , Oct. 01, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced growing adoption of SteraMist iHP technology in India's pharmaceutical sector through its partner, STS Technocrat (India) Pvt. Ltd.
STS Technocrat (India) Pvt. Ltd. is one of India's leading providers of technology solutions for the pharmaceutical, healthcare, food and beverage, cosmetics, and HoReCa (hotel, restaurant and catering) industries. In addition to distributing SteraMist, STS Technocrat (India) Pvt. Ltd. is working with TOMI to manufacture a turnkey, fully integrated SteraMist iHP enclosure.
STS Technocrat (India) Pvt. Ltd. recently signed a well-known pharmaceutical company as a SteraMist customer. This win gives SteraMist a strong reference site in the region, and STS Technocrat (India) Pvt. Ltd. is already building on it with several more opportunities in the pharmaceutical sector. In the United States, customer referrals have been one of the strongest drivers of SteraMist iHP adoption across life sciences, and TOMI expects the same pattern in India as STS Technocrat (India) Pvt. Ltd. expands its reach.
India is one of the world's fastest-growing pharmaceutical markets. According to iMarc group, the market grew from USD 68.38 billion in 2025 to USD 75.89 billion in 2026. The market is projected to reach USD 174.67 billion by 2034, growing at a compound annual growth rate (CAGR) of
“We are making strong strides in the Indian market with SteraMist iHP decontamination technology,” said Sachin Utekar, Director of STS Technocrat (India) Pvt. Ltd. “We already have an established client base that aligns well with SteraMist iHP decontamination technology. We look forward to continuing our collaboration with TOMI on the integrated SteraMist iHP enclosure and expanding across the region.”
For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com.
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company providing environmental disinfection and bio-decontamination solutions through manufacturing, sales, and licensing of its Binary Ionization Technology® (BIT®) platform. Developed under a defense grant with DARPA, BIT® utilizes low-percentage hydrogen peroxide to produce ionized hydrogen peroxide (iHP®) fog. SteraMist® products serve hospitals, laboratories, government and military installations, cruise ships, office buildings, schools, restaurants, food processing facilities, and residences, delivering protection against a broad range of bacteria, viruses, mold, mycotoxins, and biological and chemical warfare agents. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the life sciences sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Zach Nevas
IMS Investor Relations
tomi@imsinvestorrelations.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How is TOMI expanding SteraMist in India's pharmaceutical market?
TOMI's partner STS Technocrat has signed an unnamed pharmaceutical company as a SteraMist customer in India. The partner also distributes SteraMist and is working with TOMI to manufacture a fully integrated SteraMist iHP enclosure.